HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series.

Abstract
The COVID-19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT-P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.
AuthorsSooraj Vijayan, Kyungmin Hwangbo, Nick Barkham
JournalClinical case reports (Clin Case Rep) Vol. 10 Issue 1 Pg. e05233 (Jan 2022) ISSN: 2050-0904 [Print] England
PMID35059197 (Publication Type: Case Reports)
Copyright© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: